GlassScriptPhysician profile
Joseph Amos
NPI 1861668493
$83,794.32
in general payments reported to CMS, 2019-2025
28 companies · $1,809 in 2025
The $1,809 reported for 2025 was more than what 77% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46K · 2020: $1,855 · 2021: $9,193 · 2022: $13K · 2023: $9,348 · 2024: $1,835 · 2025: $1,809.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,569 · Education: $4,275 · Travel and Lodging: $2,547 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $1,600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,569.38 |
| Education | $4,275.00 |
| Travel and Lodging | $2,547.33 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $1,600.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $70,124.80 | 2019-2024 | Omnia, Senza |
| Painteq LLC | $5,150.57 | 2022-2024 | Painteq |
| Saluda Medical Americas, INC. | $1,822.07 | 2023 | Evoke Scs |
| Biotronik Nro, INC. | $1,439.06 | 2024-2025 | Prospera |
| Boston Scientific Corporation | $1,119.42 | 2024 | Intracept |
| Vertiflex, INC. | $1,015.45 | 2019 | |
| Abbott Laboratories | $578.18 | 2019-2023 | Proclaim |
| Abbvie INC. | $560.28 | 2023-2025 | Botox, Qulipta, Ubrelvy |
| Spr Therapeutics, INC | $423.26 | 2021-2025 | Sprint Pns System |
| Globus Medical, INC. | $346.07 | 2025 | Senza |
| Stryker Corporation | $336.44 | 2019 | |
| Vertos Medical, INC. | $243.33 | 2021-2023 | Mild Device Kit |
| Mml US, INC. | $131.87 | 2023 | Reactiv8 |
| Novartis Pharmaceuticals Corporation | $67.37 | 2023-2024 | |
| Pfizer INC. | $57.16 | 2020-2024 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $56.73 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $48.12 | 2023-2024 | Gammagard, Hyqvia |
| Medtronic, INC. | $37.91 | 2021-2022 | |
| Relievant Medsystems, INC. | $37.65 | 2021-2023 | Intracept |
| Averitas Pharma INC. | $28.04 | 2023 | Qutenza |
| Ucb, INC. | $26.38 | 2024 | Rystiggo |
| Biogen, INC. | $25.15 | 2023 | Vumerity, Tysabri |
| Medtronic USA, INC. | $24.56 | 2020 | |
| Azurity Pharmaceuticals, INC. | $22.86 | 2025 | Horizant |
| International Rehabilitative Sciences, INC | $20.47 | 2023 | Rs 4i Plus Sequential Stimulator |
| Si-Bone, INC. | $17.69 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.93 | 2025 | Relistor |
| Ibsa Pharma INC. | $16.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Amos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.